URGN UroGen Pharma Ltd.

32.46
-0.55  -2%
Previous Close 33.01
Open 33.11
Price To Book 2.82
Market Cap 674,890,305
Shares 20,791,445
Volume 112,212
Short Ratio
Av. Daily Volume 193,742

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be completed 2H 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Phase 2a planned for 1H 2019.
Vesimune
Carcinoma In-Situ (CIS)
Phase 2b initial data due 2H 2019.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)
Initiation of rolling NDA announced December 17, 2018. Phase 3 data May 5, 2019 noted 59% CR. 6-month CR durability 89%. Full Phase 3 data due 2H 2019.
MitoGel - UGN-101
Urothelial Carcinoma

Latest News

  1. Hedge Funds Have Never Been This Bullish On UroGen Pharma Ltd. (URGN)
  2. UroGen Pharma Joins Russell 3000® Index
  3. UroGen Pharma to Present at June 2019 Investor Conferences
  4. 3 Top Stocks That Aren't on Wall Street's Radar
  5. These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month
  6. UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript
  7. UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments
  8. Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy?
  9. What Are Analysts Saying About UroGen Pharma Ltd.'s (NASDAQ:URGN) Earnings Outlook?
  10. UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial
  11. UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
  12. UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen
  13. 3 International Companies Making Waves in the U.S. Soon
  14. 1 Under-the-Radar Healthcare Stock Wall Street Is Overlooking
  15. UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer
  16. What Type Of Shareholder Owns UroGen Pharma Ltd.’s (NASDAQ:URGN)?
  17. UroGen Pharma to Present at March 2019 Investor Conferences
  18. UroGen Pharma Ltd. (URGN) Q4 2018 Earnings Conference Call Transcript
  19. UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results
  20. UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019